GlassScriptPhysician profile
Olivia F Smith
NPI 1922504034
$1,266.66
in general payments reported to CMS, 2019-2025
22 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.53 · 2023: $164 · 2024: $508 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $193.31 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Gilead Sciences, INC. | $175.97 | 2023-2024 | Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.07 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $102.14 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $76.09 | 2023-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $74.53 | 2022 | |
| Abbvie INC. | $71.99 | 2024-2025 | |
| Alkermes, INC. | $53.98 | 2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $41.03 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $38.47 | 2024-2025 | Spravato, Invega Sustenna |
| Glaxosmithkline, LLC. | $34.65 | 2023 | Shingrix |
| Corium, LLC | $32.62 | 2024-2025 | Azstarys |
| Lundbeck LLC | $32.47 | 2024 | Rexulti |
| Pfizer INC. | $21.97 | 2024 | |
| Lilly USA, LLC | $21.32 | 2025 | Zepbound, Mounjaro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $20.57 | 2025 | Dyanavel Xr |
| Organon LLC | $19.82 | 2024 | |
| Almatica Pharma LLC | $18.44 | 2024 | Loreev Xr |
| Viiv Healthcare Company | $18.09 | 2025 | Apretude |
| Biogen, INC. | $18.07 | 2025 | Zurzuvae |
| Indivior INC. | $17.95 | 2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $14.11 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.